Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2307563 (2023).

Article  PubMed  Google Scholar 

Knop, F. K. et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 705–719 (2023).

Article  CAS  PubMed  Google Scholar 

Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).

Article  CAS  PubMed  Google Scholar 

Wadden, T. A. et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat. Med. 29, 2909–2918 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frias, J. P. et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 402, 720–730 (2023).

Article  CAS  PubMed  Google Scholar 

Kizilkaya, H. S. et al. Loss of function glucose-dependent insulinotropic polypeptide receptor variants are associated with alterations in BMI, bone strength and cardiovascular outcomes. Front. Cell Dev. Biol. 9, 749607 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Strande, J. L. et al. A phase 1, randomized, double-blind, placebo-controlled single and multipleascending dose study of AMG 133 in subjects with obesity. Metabolism 142 (Suppl.), 155433 (2023).

Article  Google Scholar 

Killion, E. A. et al. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nat. Commun. 11, 4981 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5, e140532 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Wharton, S. et al. Daily Oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. 389, 877–888 (2023).

Article  CAS  PubMed  Google Scholar